何杰金淋巴瘤不仅在生物学和病理学上与非何杰金淋巴瘤不同,而其在诊断和治疗进展上也独具特征。近25年,通过大视野放疗和联合化疗,预后有了很大改善,约75%痊愈。早、中期的治愈率分别为90%和80%。近几年,降低了急性和慢性毒性反应(内分泌病、第二肿瘤)。反之,进展期的患者须给予 Hodgkin’s lymphoma is not only biologically and pathologically distinct from non-Hodgkin’s lymphoma, but it is also unique in its diagnosis and treatment. In the past 25 years, the prognosis has been greatly improved through extensive field radiotherapy and combined chemotherapy, and about 75% of patients have recovered. Early and mid-term cure rates were 90% and 80%. In recent years, acute and chronic toxicity has been reduced (endocrinopathy, second tumor). Conversely, patients with advanced disease should be given